Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 1(4)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02893618Phase 2Unknown

A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

Role: lead

NCT00901823Phase 1Withdrawn

Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline

Role: lead

NCT00973271Phase 3Withdrawn

Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

Role: lead

NCT02034071Phase 1Completed

Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Role: lead

NCT01211847Phase 2Completed

Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

Role: lead

NCT01211860Phase 1Completed

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

Role: lead

NCT00688857Phase 1Completed

Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations

Role: lead

NCT00696475Phase 2Completed

Diazoxide Choline in Hypertriglyceridemia

Role: lead

All 8 trials loaded